StageZero Life Sciences Ltd (SZLS) NPV
StageZero Life Sciences Ltd. is a Canada-based company focused on developing and commercializing molecular diagnostic tests for early detection of cancer. It has developed Sentinel Principle platform technology, which determines biomarkers from whole blood. In additional, the Company offers ColonSentry product, it is a blood test to determine an individual’s current risk for having colorectal cancer. It is developing cancer testing kit Aristotle, which is a multi-cancer panel for simultaneously screening for 10 cancers from a single sample of blood. The Company is also focused on testing Aristotle application on other disease conditions including neurology, gastroenterology, cardiology, and autoimmune disorders.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.